Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 (Faldaprevir) in HCV Genotype 1
NCT00984620Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 6
01
Overview
A Phase 2 trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Started Sep 2009; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00984620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984620.